Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-escalation and expansion study of intravenous HBI-3000 for recent-onset atrial fibrillation conversion
2022-001021-74Phase 2Completed
- Sponsor
- HUYABIO International, LLC
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sulcardine in Atrial fibrillation (AFib), sponsored by HUYABIO International, LLC. Primary endpoint: Primary efficacy endpoint. Started Mar 2023; status: completed.
02
Drugs
sulcardine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2022-001021-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001021-74.